Notas del episodio
On Day 2 of ASH 2024, we explore breakthroughs in treating high-risk smoldering multiple myeloma, advancements in chronic lymphocytic leukemia therapies, and a revealing study on leukemia risk in Ground Zero first responders. Stay updated with insights that are reshaping hematology practice.
Love what you hear? Download the Curie app for daily updates and bonus episodes tailored for oncology professionals.
Palabras clave
HealthcareMedicineDeepdivePodcastASHASH2024Oncologyhematology